总的来说，2025 年 ELN-DAVID 共识文件为 AML MRD 评估提供了全面的标准化框架。新共识引入了「低水平阳性（MRD-LL）」 及「最佳、警示、高风险」的定性反应分类，并细化了 MFC 和分子技术的检测阈值。此外，共识也明确了 ...

Acute myeloid leukemia (AML) is a type of blood and bone marrow cancer. AML can affect people of any age, but it is most common in adults. AML occurs when bone marrow produces abnormal blood cells, ...

AVEO Oncology, an LG Chem company, (AVEO) announced today that the first patient has been successfully dosed in a Phase 1b/2 clinical trial evaluating ficlatuzumab in combination with azacitidine and ...

New research co-led by Indiana University School of Medicine scientists has exposed a vulnerability in acute myeloid leukemia ...

Pediatric acute myeloid leukemia (AML) is one of the most common acute leukemias in children. While treatment outcomes have ...

Supports capital-efficient expansion of the SLS009 clinical program into frontline AML, enabling broader U.S. and European patient enrollment ...

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates. Led by Mikkael ...

The blood cancers acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are extremely challenging to treat. While advances in immunotherapy have cured many patients with other blood cancers, ...

Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than those ...

NEW YORK, Nov. 7, 2024 /PRNewswire/ -- Report with the AI impact on market trends - The acute myeloid leukemia (AML) treatment market in APAC size is estimated to grow by USD 305.8 million from ...